ATE248602T1 - Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien - Google Patents

Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien

Info

Publication number
ATE248602T1
ATE248602T1 AT94920784T AT94920784T ATE248602T1 AT E248602 T1 ATE248602 T1 AT E248602T1 AT 94920784 T AT94920784 T AT 94920784T AT 94920784 T AT94920784 T AT 94920784T AT E248602 T1 ATE248602 T1 AT E248602T1
Authority
AT
Austria
Prior art keywords
presented
methods
antigens
antigen
cell lines
Prior art date
Application number
AT94920784T
Other languages
English (en)
Inventor
Steven A Porcelli
Michael B Brenner
Evan Beckman
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE248602T1 publication Critical patent/ATE248602T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94920784T 1993-06-21 1994-06-21 Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien ATE248602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8007293A 1993-06-21 1993-06-21
PCT/US1994/006991 WO1995000163A1 (en) 1993-06-21 1994-06-21 Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods

Publications (1)

Publication Number Publication Date
ATE248602T1 true ATE248602T1 (de) 2003-09-15

Family

ID=22155084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94920784T ATE248602T1 (de) 1993-06-21 1994-06-21 Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien

Country Status (8)

Country Link
EP (1) EP0751780B1 (de)
JP (2) JPH08511939A (de)
AT (1) ATE248602T1 (de)
CA (1) CA2165786A1 (de)
DE (1) DE69433115T2 (de)
DK (1) DK0751780T3 (de)
ES (1) ES2201078T3 (de)
WO (1) WO1995000163A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6238676B1 (en) 1992-12-10 2001-05-29 Brigham And Women's Hospital Presentation of hydrophobic antigens to T-cells by CD1 molecules
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
NZ283784A (en) 1994-04-14 1998-08-26 Adcock Ingram Ltd Diagnostic assay for mycobacterium and intracellular antigen
CA2202680A1 (en) * 1994-10-13 1996-04-25 Robert L. Modlin Presentation of hydrophobic antigens to t-cells by cd1 molecules
AU720288B2 (en) * 1995-02-22 2000-05-25 Adcock Ingram Limited A method for the isolation and purification of lipid cell-wall components
CA2243235C (en) * 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
WO1998039025A2 (en) 1997-03-03 1998-09-11 Adcock Ingram Limited A composition comprising a carrier and a purified mycobacterial lipid cell-wall component and its use in the prevention, treatment and diagnosis of disease
EP1372668B1 (de) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Verfahren zur abschwächung von reaktionen auf hautreizende mittel
WO2004093903A2 (en) * 2003-04-18 2004-11-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation using cd1 antigens
WO2006060117A2 (en) 2004-11-02 2006-06-08 The Board Of Trustees Of The Leland Stanford Junior University Methods for inhibition of nkt cells
EP2047860A1 (de) * 2007-10-12 2009-04-15 Centre National De La Recherche Scientifique (Cnrs) Pharmazeutische Zusammensetzungen mit Actinomycet-Glycerin-Acyl-Derivat-Antigenen, Verfahren zu deren Extraktion und ihre Verwendung gegen Tuberkulose
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin

Also Published As

Publication number Publication date
DE69433115D1 (de) 2003-10-09
EP0751780B1 (de) 2003-09-03
DE69433115T2 (de) 2004-04-01
CA2165786A1 (en) 1995-01-05
JP2006104206A (ja) 2006-04-20
DK0751780T3 (da) 2003-10-13
WO1995000163A1 (en) 1995-01-05
EP0751780A1 (de) 1997-01-08
EP0751780A4 (de) 1997-12-10
ES2201078T3 (es) 2004-03-16
JPH08511939A (ja) 1996-12-17

Similar Documents

Publication Publication Date Title
Rouse et al. Expression of MHC antigens by mouse thymic dendritic cells
ATE248602T1 (de) Verfahren zur isolierung von cda-präsentierten antigenen, cd1-präsentierte antigeneenthaltende impfstoffe und in besagten verfahren verwendbare zelllinien
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
DE69333289D1 (de) Verfahren zur bestimmung von säugetier nukleinsäuren aus stuhlproben und dafür benötigte reagenzien
Buchanan et al. Activation of the cell wall degrading protease, lysin, during sexual signalling in Chlamydomonas: the enzyme is stored as an inactive, higher relative molecular mass precursor in the periplasm.
TR199501326A2 (tr) Otoimmün hastaliklarin immünoterapilerinde kullanilmak üzere otoantijenden üretilen yeni peptidler.
US20130052642A1 (en) Method for the identification and purification of human naturally occurring regulatory t cells (ntregs)
KR950008537A (ko) 엡스타인 바 비루스(ebv)에 대한 항체의 검출용 진단제
DK0755517T3 (da) Fremgangsmåde til detektion af tilstedeværelse af en Mycobacterium-art og et kit og antistoffer til anvendelse i denne
ATE200709T1 (de) Htlv-i/htlv-ii assay und verfahren
SE9602677D0 (sv) Methods for determining brain antigens
WO1996012190A3 (en) Presentation of hydrophobic antigens to t-cells by cd1 molecules
EP0165001A1 (de) Verfahren zur Identifizierung der Gruppe eines Streptococcus
Vendrell et al. In vitro antibody secretion by peripheral blood mononuclear cells as an expression of the immune response to Brucella spp. in humans
Kim et al. Characterization of a helper T cell epitope recognized by mice of a low responder major histocompatibility type
Engelkens et al. The influence of different sera on the in vitro immobilisation of Percoll purified Treponema pallidum, Nichols strain.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties